@article{3187650,
    title = "Closing the Efficacy and Effectiveness Gap: Outcomes in
Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with
Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice
Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1
Study",
    author = "Hajek, Roman and Minarik, Jiri and Straub, Jan and Pour, Ludek and and Jungova, Alexandra and Berdeja, Jesus G. and Boccadoro, Mario and and Brozova, Lucie and Spencer, Andrew and van Rhee, Frits and Vela-Ojeda, and Jorge and Thompson, Michael A. and Abonour, Rafat and Chari, Ajai and and Cook, Gordon and Costello, Caitlin L. and Davies, Faith E. and Hungria, and Vania T. M. and Lee, Hans C. and Leleu, Xavier and Puig, Noemi and and Rifkin, Robert M. and Terpos, Evangelos and Usmani, Saad Z. and Weisel, and Katja C. and Zonder, Jeffrey A. and Barinova, Magda and Kuhn, Matyas and and Silar, Jiri and Capkova, Lenka and Galvez, Kenny and Lu, Jin and Skacel, and Tomas and Elliott, Jennifer and Demers, Brittany and Marie, Dawn and and Ren, Kaili and Maisnar, Vladimir",
    journal = "Blood advances",
    year = "2019",
    volume = "134",
    number = "1",
    publisher = "AMER SOC HEMATOLOGY",
    doi = "10.1182/blood-2019-126606"
}